This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACLX Arcellx (ACLX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Arcellx Stock (NASDAQ:ACLX) Get Arcellx alerts:Sign Up Key Stats Today's Range$114.99▼$115.1350-Day Range$113.76▼$115.1052-Week Range$47.86▼$115.13Volume14.67 million shsAverage Volume1.50 million shsMarket Capitalization$6.73 billionP/E RatioN/ADividend YieldN/APrice Target$112.08Consensus RatingHold Company Overview Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers. The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development. Arcellx is advancing lead clinical candidates for relapsed or refractory blood cancers, while exploring applications in solid tumors and autoimmune indications. Manufacturing operations are conducted at the company’s proprietary facility in Malvern, Pennsylvania, with additional process development and scale-up capabilities in the greater Philadelphia region. Founded in 2018, Arcellx has established collaborations with academic centers and contract research organizations across North America and Europe to support its clinical trial activities. The company is led by an experienced management team with deep expertise in cell therapy research, clinical development and biomanufacturing. Arcellx’s leadership is committed to translating its engineered cell technology into novel treatments that can overcome the limitations of current approaches and address significant unmet medical needs.AI Generated. May Contain Errors. Read More Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACLX Stock News HeadlinesGilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celApril 28, 2026 | businesswire.comGilead extends Arcellx tender offer againApril 17, 2026 | seekingalpha.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 16 at 1:00 AM | Behind the Markets (Ad)Truist Financial Keeps Their Hold Rating on Arcellx Inc (ACLX)April 10, 2026 | theglobeandmail.comAssessing Arcellx (ACLX) Valuation After Strong Multi‑Year Share Price GainsApril 8, 2026 | finance.yahoo.comAssessing Arcellx (ACLX) Valuation After Strong Multi Period Share Price MomentumMarch 25, 2026 | finance.yahoo.comArcellx Inc.March 24, 2026 | barrons.comHalper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their ShareholdersMarch 19, 2026 | globenewswire.comSee More Headlines ACLX Stock Analysis - Frequently Asked Questions How were Arcellx's earnings last quarter? Arcellx, Inc. (NASDAQ:ACLX) released its quarterly earnings results on Thursday, February, 26th. The company reported ($1.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.01). The firm had revenue of $1.65 million for the quarter, compared to the consensus estimate of $13.40 million. Arcellx had a negative trailing twelve-month return on equity of 55.42% and a negative net margin of 1,027.26%. When did Arcellx IPO? Arcellx (ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share. What other stocks do shareholders of Arcellx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcellx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Block (XYZ), PayPal (PYPL), Oklo (OKLO) and Broadcom (AVGO). Company Calendar Today11/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACLX CIK1786205 Webarcellx.com Phone240-327-0603FaxN/AEmployees80Year Founded2015Price Target and Rating Average Price Target for Arcellx$112.08 High Price Target$120.00 Low Price Target$82.00 Potential Upside/Downside-2.6%Consensus RatingHold Rating Score (0-4)2.06 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$228.93 million Net Margins-1,027.26% Pretax Margin-1,026.94% Return on Equity-55.42% Return on Assets-36.24% Debt Debt-to-Equity RatioN/A Current Ratio4.44 Quick Ratio4.44 Sales & Book Value Annual Sales$22.29 million Price / Sales301.95 Cash FlowN/A Price / Cash FlowN/A Book Value$6.96 per share Price / Book16.53Miscellaneous Outstanding Shares58,480,000Free Float53,597,000Market Cap$6.73 billion OptionableOptionable Beta0.25 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ACLX) was last updated on 4/28/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.